These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30588023)

  • 1. Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment.
    Lai J; Du B; Wang Y; Wu R; Yu Z
    Onco Targets Ther; 2018; 11():9111-9116. PubMed ID: 30588023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.
    Jiang N; Zhou J; Zhang W; Li P; Liu Y; Shi H; Zhang C; Wang Y; Zhou C; Peng C; Zhang W; Hao Y; Sun Q; Li Y; Zhao X
    Thorac Cancer; 2021 Jan; 12(2):181-193. PubMed ID: 33200540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
    Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
    Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer.
    Zhang M; Wu J; Zhong W; Zhao Z; Guo W
    Transl Cancer Res; 2022 May; 11(5):1245-1254. PubMed ID: 35706796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
    Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
    Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients.
    Kim S; Kim S; Kim SH; Jung EH; Suh KJ; Kim YJ; Kwon NJ; Kim H; Chung JH; Lee JS
    Transl Lung Cancer Res; 2023 Jun; 12(6):1185-1196. PubMed ID: 37425402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer.
    Yin JX; Hu WW; Gu H; Fang JM
    J Cancer; 2021; 12(4):1258-1269. PubMed ID: 33442424
    [No Abstract]   [Full Text] [Related]  

  • 20. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.